Health & Medicine | Jan 8, 2026 | 8 min read | By Bryan White

How Global Chemistry and Geopolitics Triggered a Fentanyl Supply Shock and Decline in Overdose Mortality

Biology * Public Health * Urban Environment

The Synthetic Paradigm and the 2024-2025 Mortality Contraction

The American opioid epidemic -- a public health crisis that has claimed over one million lives since 2000 -- was defined for over two decades by rising mortality across prescription opioids, heroin, and synthetic opioids.[1] However, provisional data from the Centers for Disease Control and Prevention (CDC) for 2024 revealed a sharp inflection: a 26.9% contraction in national drug overdose mortality, dropping from 110,037 deaths in 2023 to 80,391 in provisional 2024 reporting, with synthetic opioid fatalities falling by 36.5%.[3] Subsequent CDC National Center for Health Statistics data released on May 13, 2026 confirmed that the decline continued for a third consecutive year in 2025, falling almost 14% further to an estimated 69,973 overdose deaths (down from a revised 2024 total of 81,313), with provisional Vital Statistics Rapid Release tracking continuing through 2026.[4][5] Triangulating epidemiological mortality curves, customs seizure statistics, and diplomatic records demonstrates that this contraction resulted from an upstream global precursor supply shock triggered by resumed U.S.-China counternarcotics enforcement in late 2023, compounded by domestic naloxone saturation.[1][2]

Unlike plant-based narcotics such as heroin (derived from Papaver somniferum), illicitly manufactured fentanyl (IMF) decoupled the drug trade from agricultural land, weather, and bulk smuggling.[1] Because fentanyl is 50 to 100 times more potent than morphine, transnational criminal organizations achieved logistical efficiency by synthesizing compact batches in clandestine laboratories and pressing counterfeit oxycodone ("M30") pills.[1][7] For years, this dynamic reflected the "Iron Law of Prohibition," whereby intensified interdiction pushes traffickers toward higher-potency, lower-volume molecules.[7] By 2023, counterfeit fentanyl tablets had saturated West Coast and East Coast markets alike.[7] Yet the industrial nature of synthetic opioids also introduced a structural vulnerability: dependence on specialized chemical precursors.[1]

The Chemistry of Control: The Siegfried Method and Masked Precursors

Clandestine laboratories widely use the three-step "Siegfried Method" of fentanyl synthesis, which bypasses the complex pharmaceutical Janssen route.[16] Step 1 establishes the molecular piperidine-phenethyl backbone using N-phenethyl-4-piperidone (NPP). In Step 2 (reductive amination), NPP is reacted with aniline in the presence of a reducing agent such as sodium borohydride, stripping the double-bonded oxygen atom from the piperidine ring and replacing it with the aniline group to yield the immediate precursor 4-anilino-N-phenethylpiperidine (4-ANPP).[16] In Step 3 (acylation), 4-ANPP is treated with propionyl chloride (or propionic anhydride), attaching a propionyl chain to the aniline nitrogen atom to produce fentanyl.[16]

After international scheduling and Chinese controls on NPP and 4-ANPP took effect in 2017-2018, grey-market chemical suppliers pivoted to "masked precursors" (designer precursors) and upstream pre-precursors.[16] By attaching a tert-butyloxycarbonyl ("boc") protecting group to create 1-boc-4-AP, brokers exported an unscheduled intermediate that illicit chemists could cleave back into 4-ANPP via simple acid treatment, or synthesized NPP directly from 4-piperidone and phenethyl bromide.[1][16]

| Chemical Name | | Abbreviation | | Role in Fentanyl Synthesis | | Regulatory Status |

| N-phenethyl-4-piperidone | | NPP | | Primary Piperidine Backbone (Siegfried Step 1) | | List I Controlled (US / China / UN) |

| 4-anilino-N-phenethylpiperidine | | 4-ANPP | | Immediate Precursor (Siegfried Step 2) | | List I Controlled (US / China / UN) |

| tert-butyl 4-(phenylamino)piperidine-1-carboxylate | | 1-boc-4-AP | | "Masked" Acid-Cleavable Precursor | | List I Controlled (US / China Notice) |

| 4-piperidone | | -- | | Upstream Pre-Precursor Intermediate | | List I Controlled (US) / Dual-Use |

| Propionyl Chloride | | -- | | Acylating Reagent (Siegfried Step 3) | | List I Controlled (US) / Dual-Use |

Geopolitical Pivot and Just-in-Time Trafficking Fragility

Following the August 2022 suspension of bilateral counternarcotics cooperation between Beijing and Washington, online chemical brokers marketed masked precursors with minimal interference.[2] The geopolitical turning point arrived at the November 2023 Woodside Summit in California between Presidents Joe Biden and Xi Jinping: the United States removed the Chinese Ministry of Public Security's Institute of Forensic Science from the Commerce Entity List in exchange for resumed Chinese counternarcotics enforcement.[8]

Chinese authorities issued regulatory notices to domestic chemical firms covering U.S.-controlled precursors and warning brokers against exporting dual-use or masked intermediates destined for illicit synthesis.[2] Paired with U.S. Department of Justice indictments targeting Chinese precursor suppliers (such as Hubei Aoks Bio-Tech) and Chinese shutdowns of B2B storefronts and payment accounts, the enforcement wave disrupted exports.[9][15]

This crackdown struck trafficking networks at an acute logistical vulnerability.[1] To avoid warehouse raids and capital lockup, cartels operated on a "Just-in-Time" inventory model reliant on continuous sea and air shipments.[10] Lacking strategic precursor reserves, cartel synthesis pipelines contracted rapidly by early 2024, triggering street purity fluctuations, reduced seizures, and steep mortality declines.[5][7]

Domestic Harm Reduction, Naloxone Saturation, and Xylazine Adulteration

The upstream supply shock acted alongside expanded domestic public health interventions. Funded by federal grants and opioid litigation settlements, states achieved broad community naloxone distribution.[11] Ohio's "RecoveryOhio" initiative distributed over 291,000 naloxone kits in 2023 across emergency rooms, clinics, and vending machines, helping drive a steep drop in state overdose fatalities.[11] Widespread adoption of fentanyl test strips and Michigan's expanded medications for opioid use disorder further reduced lethality per overdose event.[6][11]

Concurrently, precursor scarcity accelerated street fentanyl adulteration with xylazine, a non-opioid veterinary sedative.[12] While xylazine causes necrotic skin ulcers and sedation unresponsive to naloxone, toxicological patterns indicate that bulking counterfeit supplies with xylazine lowered absolute fentanyl milligram content per dose, shifting immediate respiratory mortality dynamics even as soft-tissue morbidity rose.[7][12]

CDC Provisional Overdose Mortality Contraction (2023 vs. 2024 Initial Release; 2025 Revised to 69,973 Total)

| Substance Category | | Estimated Deaths (2023) | | Provisional Deaths (2024 Release) | | 12-Month % Change |

| Total Drug Overdose Deaths | | 110,037 | | 80,391 (revised 81,313; 2025: 69,973) | | -26.9% (2024); -14.0% (2025) |

| Synthetic Opioids (Primarily Fentanyl) | | 76,282 | | 48,422 | | -36.5% |

| Psychostimulants (Methamphetamine) | | 37,096 | | 29,456 | | -20.6% |

| Cocaine | | 30,833 | | 22,174 | | -28.1% |

| Natural & Semi-Synthetic Opioids | | 10,511 | | 8,006 | | -23.8% |

Regional Variation in State Overdose Trajectories (2023-2024)

| State | | Mortality Shift (2023-2024) | | Primary Epidemiological Context |

| Ohio | | >35% Decline | | Wide naloxone distribution (>291k kits via RecoveryOhio)[11] |

| Michigan | | ~34% Decline | | Expanded MAT access, naloxone saturation, and harm reduction infrastructure[6] |

| North Carolina | | >30% Decline | | Sharp contraction in East Coast white-powder fentanyl purity (continuing 25% drop in 2025)[3][4] |

| Nevada & Alaska | | Net Increase (2024) | | Delayed West Coast counterfeit pill wave and rural access gaps[3][7] |

The Iron Law of Prohibition and the Emerging Nitazene Threat

Despite the magnitude of the 2024-2025 mortality decline, the Iron Law of Prohibition warns that illicit markets adapt to precursor choke points by migrating toward unscheduled, higher-potency chemical families.[13] A primary concern for the

durability of the fentanyl downturn is the emergence of nitazenes (2-benzylbenzimidazole opioids), including isotonitazene, metonitazene, and protonitazene.[13][14]

Synthesized first in the 1950s and never approved for clinical use, nitazenes lack the piperidine ring structure of fentanyl and therefore require neither NPP nor 4-ANPP.[13] Built instead from unregulated benzimidazole intermediates, protonitazene exhibits analgesic and respiratory-depressant potency far exceeding morphine (surpassing fentanyl in mu-opioid receptor affinity) and has appeared in toxicology seizures across North America and the United Kingdom.[13][14] Furthermore, because Chinese precursor enforcement remains contingent on U.S.-China diplomatic relations, bilateral disruptions could reopen illicit chemical pipelines.[2][15]

Comparative Potency and Precursor Dependency Across Opioid Classes

| Substance | | Potency Relative to Morphine | | Primary Precursor Architecture |

| Morphine / Heroin | | 1x / 2x-5x | | Agricultural Opium Poppy (Papaver somniferum) |

| Fentanyl | | 50x-100x | | Piperidine Ring (NPP / 4-ANPP / 1-boc-4-AP) |

| Carfentanil | | ~10,000x | | Piperidine Ring (NPP Derivative) |

| Isotonitazene | | 5x-20x | | Benzimidazole Scaffolds (Non-NPP / Unscheduled) |

| Protonitazene | | 20x-60x (Up to 3x Fentanyl) | | Benzimidazole Scaffolds (Non-NPP / Unscheduled) |

Fragile Equilibrium in the Synthetic Opioid Market

The consecutive 2024 and 2025 reductions in U.S. overdose deaths -- bringing annual fatalities down from 110,037 in 2023 to 69,973 in 2025 -- demonstrate that synthetic drug epidemics are sensitive to upstream chemical choke points.[3][4] By targeting precursors and masked intermediates of the Siegfried pathway after the November 2023 Woodside Summit, bilateral enforcement disrupted Just-in-Time cartel logistics and amplified domestic naloxone distribution.[1][8] Sustaining this downward curve requires pairing agile international precursor controls against benzimidazole nitazenes with permanent addiction treatment and harm reduction infrastructure.[13][15]

Updates... (Nov 23, 2026): Replaced the 403-restricted MDHHS press release in Reference [6] with Bridge Michigan's accessible MDHHS reporting (Jun 6, 2025) and aligned Michigan's 2024 mortality decline (~34%); replaced off-topic and commercial citations in References [10], [11], and [16] with Science (Vangelov et al., Jan 8, 2026), official Ohio Department of Mental Health & Addiction Services data (Oct 30, 2024), and Journal of Analytical Toxicology (Vandeputte et al., Apr 2, 2021) covering Siegfried-route precursors and 1-boc-4-AP; and marked CDC VSRR Reference [5] as a rolling series. (Prior Nov 20, 2026 update added 2025 CDC NCHS mortality totals of 69,973 deaths.)

References

* [1] U.S. Government Accountability Office. (Aug 14, 2025). Fentanyl Continues to Be the Leading Cause of Overdose Deaths. What's Being Done to Combat Trafficking into the United States? https://www.gao.gov/blog/fentanyl-continues-be-leading-cause-overdose-deaths.-whats-being-done-combat-trafficking-united-states

* [2] ASPI The Strategist. (Aug 23, 2024). No, China isn't really suppressing its production of fentanyl precursors. https://www.aspistrategist.org.au/no-china-isnt-really-suppressing-its-production-of-fentanyl-precursors/

* [3] CDC National Center for Health Statistics. (May 14, 2025). U.S. Overdose Deaths Decrease Almost 27% in 2024. https://www.cdc.gov/nchs/pressroom/releases/20250514.html

* [4] CDC National Center for Health Statistics. (May 13, 2026). U.S. Overdose Deaths Decrease for Third Consecutive Year in 2025. https://www.cdc.gov/nchs/pressroom/releases/20260513.html

* [5] CDC National Center for Health Statistics. (Nov 10, 2026; rolling monthly release). Vital Statistics Rapid Release: Provisional Drug Overdose Data. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

* [6] Bridge Michigan. (Jun 6, 2025). A steep drop in Michigan overdose deaths, thanks in part to Narcan. https://bridgemi.com/michigan-health-watch/steep-drop-michigan-overdose-deaths-thanks-part-narcan/

* [7] Tanz, L. J., Stewart, A., Gladden, R. M., Ko, J. Y., et al. (Dec 5, 2024). Detection of Illegally Manufactured Fentanyls and Carfentanil in Drug Overdose Deaths -- United States, 2021-2024. MMWR. Morbidity and Mortality Weekly Report, 73(48), 1099-1105. https://doi.org/10.15585/mmwr.mm7348a2

* [8] U.S. Department of Commerce / Federal Register. (Nov 17, 2023). Entity List Removal (88 FR 80115). https://www.federalregister.gov/documents/2023/11/17/2023-25557/entity-list-removal

* [9] U.S. Immigration and Customs Enforcement. (Nov 14, 2024). Chinese Chemical Company, Senior Leaders Indicted for Suspected Fentanyl Manufacturing, Distribution. https://www.ice.gov/news/releases/chinese-chemical-company-senior-leaders-indicted-suspected-fentanyl-manufacturing

* [10] Vangelov, K., Humphreys, K., Caulkins, J. P., Pollack, H., Pardo, B., & Reuter, P. (Jan 8, 2026). Did the illicit fentanyl trade experience a supply shock? Science, 391(6781), 134-136. https://doi.org/10.1126/science.aea6130

* [11] Ohio Department of Mental Health and Addiction Services / Office of Governor Mike DeWine. (Oct 30, 2024). Governor DeWine: Ohio's Overdose Deaths Drop for Second Consecutive Year, Outperforming National Average. https://dbh.ohio.gov/about-us/media-center/news/pressrelease-10.30.2024

* [12] National Institute on Drug Abuse (NIDA). (Apr 21, 2022). Xylazine. https://nida.nih.gov/research-topics/xylazine

* [13] Pereira, J. R. P., Quintas, A., & Neng, N. R. (Sep 26, 2025). Nitazenes: The Emergence of a Potent Synthetic Opioid Threat. Molecules, 30(19), 3890. https://doi.org/10.3390/molecules30193890

* [14] UK Office for Health Improvement and Disparities. (Oct 3, 2024). Deaths linked to potent synthetic opioids. https://www.gov.uk/government/publications/deaths-linked-to-potent-synthetic-opioids/deaths-linked-to-potent-synthetic-opioids

* [15] Lowy Institute. (Nov 14, 2025). The US-China fentanyl deal will not stop America's opioid crisis. https://www.lowyinstitute.org/the-interpreter/us-china-fentanyl-deal-will-not-stop-america-s-opioid-crisis

* [16] Vandeputte, M. M., Krotulski, A. J., Hulpia, F., Van Calenbergh, S., & Stove, C. P. (Apr 2, 2021; print Apr 21, 2022). Phenethyl-4-ANPP: A Marginally Active Byproduct Suggesting a Switch in Illicit Fentanyl Synthesis Routes. Journal of Analytical Toxicology, 46(4), 350-357. https://doi.org/10.1093/jat/bkab032